icrf 198 has been researched along with cardiovascular agents in 5 studies
| Studies (icrf 198) | Trials (icrf 198) | Recent Studies (post-2010) (icrf 198) | Studies (cardiovascular agents) | Trials (cardiovascular agents) | Recent Studies (post-2010) (cardiovascular agents) |
|---|---|---|---|---|---|
| 24 | 0 | 4 | 17,645 | 1,480 | 6,891 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chadwick, DP; Clark, JR; Ferrans, VJ; Hasinoff, BB; Herman, EH; Zhang, J | 1 |
| Hasinoff, BB | 1 |
| Hasinoff, BB; Schroeder, PE | 1 |
| Hrušková, K; Klimeš, J; Kovaříková, P; Stariat, J; Vávrová, K | 1 |
| Klimes, J; Kovarikova, P; Pasakova-Vrbatova, I; Simunek, T; Stariat, J; Vavrova, A | 1 |
5 other study(ies) available for icrf 198 and cardiovascular agents
| Article | Year |
|---|---|
Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Chelating Agents; Diketopiperazines; DNA Topoisomerases, Type II; Doxorubicin; Ethylenediamines; Glycine; Heart; Hydrolysis; Iron; Male; Myocardium; Piperazines; Rats; Rats, Inbred SHR; Razoxane | 1997 |
Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Ethylenediamines; Extracorporeal Membrane Oxygenation; Fluoresceins; Fluorescent Dyes; Glycine; Hypoxia; Ion Transport; L-Lactate Dehydrogenase; Models, Cardiovascular; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Razoxane; Time Factors; Treatment Failure | 2002 |
The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Topics: Animals; Biotransformation; Cardiovascular Agents; Chelating Agents; Chromatography, High Pressure Liquid; Ethylenediamines; Fluoresceins; Glycine; Half-Life; Indicators and Reagents; Infusions, Intravenous; Iron; Male; Molecular Structure; Rats; Rats, Sprague-Dawley; Razoxane | 2002 |
Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites--the cardioprotectant dexrazoxane as a model case.
Topics: Cardiovascular Agents; Chromatography, Liquid; Ethylenediamines; Glycine; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Models, Chemical; Razoxane; Tandem Mass Spectrometry; Temperature | 2011 |
Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium.
Topics: Animals; Animals, Newborn; Cardiovascular Agents; Cells, Cultured; Chromatography, Liquid; Ethylenediamines; Glycine; Myocytes, Cardiac; Pilot Projects; Rabbits; Rats; Rats, Wistar; Razoxane; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2013 |